Article Details

Takeda pays $300M to license Protagonist drug for blood disorder | BioPharma Dive

Retrieved on: 2024-02-01 16:58:49

Tags for this article:

Click the tags to see associated articles and topics

Takeda pays $300M to license Protagonist drug for blood disorder | BioPharma Dive. View article details on hiswai:

Summary

Biotechnology company Protagonist Therapeutics partners with Takeda Pharmaceutical to advance rusfertide, a treatment for polycythemia vera. Deal includes hefty payments, royalties, co-promotion options in the U.S., and reflects biotech collaboration within the pharmaceutical industry.

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up